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CASE REPORT
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Intravenous amphotericin B is a key component of the antifungal therapy for cryptococcal meningitis recommended in South 
African and international guidelines. Unfortunately, its use is associated with significant toxicity including deterioration in renal 
function, electrolyte disturbance, anaemia and infusion reactions. Chemical phlebitis is common following administration via 
peripheral cannulae. This can be complicated by bacterial infection, resulting in localised cellulitis or bacterial sepsis. Here 
we describe two patients with cryptococcal meningitis who developed methicillin-resistant Staphylococcus aureus (MRSA) 
bacteraemia during, or shortly after treatment with amphotericin B. These cases illustrate the dangers of line-related sepsis in 
hospitalised individuals and some of the difficulties encountered during treatment of this condition. 
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Intravenous (IV) amphotericin B is a key 
component of the antifungal therapy for crypto-
coccal meningitis (CM) recom mended in both 
South African (SA) and international guide-
lines.[1,2] Unfortunately, its use is asso ciated with 
significant toxicity including deterioration in renal function, 
electrolyte disturbance, anaemia and infusion reactions.[3] 
Chemical phlebitis is commonly seen following its administration 
via peripheral cannulae. This can be complicated by bacterial 
infection, resulting either in localised cellulitis or bacterial sepsis. 
Here we describe two patients with CM who developed 
methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia 
during, or shortly after treatment with amphotericin B. These 
cases illustrate the dangers of line-related sepsis in hospitalised 
individuals and some of the difficulties encountered during 
treatment of this condition. 
Case 1
A 42-year-old, HIV-positive man presented to hospital with 
a one-week history of headache and vomiting. He was not 
receiving antiretroviral therapy (ART) and had a CD4+ count of 
23 × 106 cells/l.
CM was diagnosed following lumbar puncture (positive 
India ink, cryptococcal antigen test and culture) and he was 
treated with 1 mg/kg/day amphotericin B (IV) and 800 mg/day 
fluconazole (oral) for 14 days. During this time he had frequent 
episodes of phlebitis at peripheral cannula sites. On day 13 
following admission, the patient deteriorated, developing fever 
and tachycardia. His right forearm was markedly swollen 
with frank pus discharging from an old cannula site. A 
diagnosis of bacterial sepsis secondary to drip-site infection 
was made, a blood culture was performed and IV vancomycin 
was administered. Within one day, S. aureus was identified 
from a blood culture. Resistance testing confirmed this to be 
methicillin-resistant, but vancomycin susceptible (minimum 
inhibitory concentration (MIC) 0.5  µg/ml). Vancomycin was 
continued with regular monitoring of trough levels. The 
patient’s fever gradually settled, and a repeat blood culture after 
7 days of therapy was negative. There were no clinical signs 
suggestive of complicated bacteraemia and the patient was 
discharged after 14 days of vancomycin therapy. He has since 
started ART and remains well 6 months later. 
Case 2
A 50-year-old HIV-positive man receiving first-line ART 
(tenofovir, lamivudine and efavirenz) presented to hospital 
with a 3-week history of headache, vomiting and blurred 


















(positive India ink, cryptococcal antigen test and culture) and treated 
with 1 mg/kg/day amphotericin B (IV) and 800 mg/day fluconazole 
(oral). Two weeks after discharge, he was seen in the infectious diseases 
clinic. Deemed to have failed first-line ART (CD4+ count 2 × 106 cells/l, 
HIV viral load 60 414 copies/ml), he was switched to zidovudine, 
lamivudine and ritonavir-boosted lopinavir. He re-presented a further 
3 weeks later with a recurrence of meningeal symptoms. Lumbar 
puncture was performed and raised intracranial pressure was noted 
(opening pressure 33 cmH2O). Amphotericin B was re-started, but 
discontinued after 7 days when cerebrospinal fluid fungal cultures 
showed no growth. The patient was diagnosed with CM immune 
reconstitution inflammatory syndrome (CM-IRIS) and treated with 
90 mg/day prednisone, with good resolution of symptoms. During 
both admissions, phlebitis was noted at amphotericin infusion sites, 
but this settled following removal of the cannula.
When seen in the outpatient clinic 2 weeks after his admission 
for IRIS, he complained of a 5-day history of fever and rigors. On 
examination, there was a tender, fluctuant mass over the inferior part of 
his sternum, but no signs of infection around any of his previous cannula 
sites. S. aureus was identified from a blood culture and needle aspirate 
of the mass; IV vancomycin was commenced pending sensitivities. A 
computed tomography (CT) scan of his chest revealed lytic destruction 
of the caudal end of the sternum with an adjacent soft-tissue collection 
(34 × 28 × 15 mm) (Fig. 1). Lung lesions suggestive of multiple septic 
emboli were also noted. A transthoracic echocardiogram showed no 
evidence of endocarditis, and a bone scan revealed no other areas 
of bone involvement. Antibiotic susceptibility testing demonstrated 
methicillin resistance, but susceptibility to vancomycin (MIC 1 µg/ml).
Incision and drainage of the chest wall abscess was performed and 
vancomycin was continued, but with little clinical improvement. Repeat 
blood cultures after 7 days of therapy remained positive for MRSA, and 
despite treatment, he deteriorated with ongoing fevers and worsening 
renal and respiratory failure. He died a week thereafter. 
Discussion
S. aureus bacteraemia is a serious infection with significant associated 
mortality. The organism is highly pathogenic and should never be 
assumed to be a blood culture contaminant, even in a patient who 
appears systemically well. The infection seeds haematogenously to 
distant organs in approximately 40% of cases, leading to endocarditis, 
septic arthritis, osteomyelitis and other deep-tissue abscesses.[4] The 
second case presented here is an illustration of this. 
In the cases described, both patients developed MRSA bacteraemia 
during, or shortly after treatment for CM; the likely portal of entry 
being peripheral venous cannulae used to administer amphotericin B 
and IV fluids. In the first case, the bacteraemia was accompanied by 
obvious signs of infection at a cannula site. In the second, no evidence 
of localised infection was found at the time of bacteraemia, but phlebitis 
(attributed to amphotericin B) had been noted during the recent 
admission. 
Although studies from North America report the risk of blood-
stream infection (BSI) associated with peripheral IV devices to be low 
(0.5 BSI/1 000 IVD days),[5] the risk could be higher in the SA setting, 
especially in this vulnerable group of patients, with advanced HIV 
infection receiving prolonged IV amphotericin B therapy. 
Diagnosing bacterial infection at IV cannula sites in patients with 
CM can be difficult, especially given the frequent chemical phlebitis 
Fig. 1. Cross-sectional computed tomography (CT) of the anterior chest (case 2). A 
lytic lesion in the sternum and overlying soft tissue mass is marked by the red oval. 
A needle aspirate of the collection grew methicillin-resistant Staphylococcus 
aureus (MRSA), as did 3 blood cultures. Limited views of the lungs showed 
multiple lesions highly suggestive of septic pulmonary emboli (not shown here).
Fig. 2. ‘Chemical’ phlebitis complicating amphotericin B infusion (photograph 
courtesy of Dr T A Bicanic). This inflammation occurred during the 4-hour 
amphotericin B infusion and presented as redness and tenderness tracking up the 
cannulated vein. In such cases, the cannula should be removed once the infusion 
is completed and the site monitored closely for infection and the patient for fever. 
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seen following amphotericin B administration (Fig. 2). Both chemical 
and infective phlebitis result in erythema and pain, and in our 
experience, infective phlebitis may occur as a complication at the site 
of chemical phlebitis. Fever and systemic upset, or the presence of pus 
at the cannula site, are very suggestive of bacterial infection and should 
be investigated further. Blood cultures should be taken prior to the use 
of any antibiotics, and swabs sent for investigation if any exudate or pus 
is present.[6] In the absence of these features, it is reasonable to remove 
the cannula, elevate the limb, apply ice and observe. Bacterial infection 
should be considered if there is no significant improvement in 24 hours, 
or it there is an expanding area of cellulitis.
If signs of systemic infection are present, then once blood cultures 
are taken, empirical IV antibiotic therapy should be commenced. 
Antibiotic choice should ensure adequate coverage of S. aureus.[6] 
Given the high rates of methicillin resistance among nosocomially 
acquired isolates in SA (30 - 60%),[7,8] IV vancomycin should be used 
until microbiology results are available. If blood cultures are negative, 
antibiotics can be stopped after 5 days.  
If blood cultures are positive for S. aureus, then more prolonged 
antibiotic treatment is required. The Infectious Diseases Society 
of America (IDSA) recommends treating uncomplicated MRSA 
bacteraemia for at least 2 weeks with IV vancomycin, with target 
trough levels of 15 - 20 μg/ml. Due to high rates of unrecognised 
endocarditis, the IDSA recommends echocardiography in all patients – 
an impractical option in many SA settings. 
A pragmatic approach is to risk stratify patients by taking repeat 
blood cultures after 2 - 4 days of antibiotic therapy. Patients with 
no implantable prostheses, no clinical evidence of endocarditis or 
metastatic infection, who have a negative repeat blood culture and 
resolution of fever within 72 hours of initiating effective therapy, can 
be treated for 2 weeks with IV vancomycin (monitoring trough levels 
and creatinine). Patients at high risk of complicated infection, such 
as those with prosthetic cardiac material, should be investigated with 
echocardiography (transoesophageal is preferred over transthoracic). 
If neither is available, high-risk patients should be treated as having 
complicated bacteraemia, with careful clinical follow-up to exclude a 
relapse of infection or complications of prosthetic-valve endocarditis. 
Patients with persistent fevers, positive repeat blood cultures or 
clinical features suggestive of metastatic infection, should be considered 
as complicated cases and investigated for endocarditis, osteomyelitis 
and deep-tissue abscesses.[4,9,10] The management of complicated MRSA 
bacteraemia should be discussed with an expert wherever possible. 
Surgery may be required to drain an abscess or remove a focus of 
infection, and antibiotic therapy should continue for approximately 
4 - 6 weeks depending on the extent of the infection and response to 
treatment.[10] 
With regard to patients with CM, it is important that clinicians are 
aware of this additional complication of amphotericin B treatment. 
Cannula sites should be monitored regularly and any patient who 
develops a new fever should be evaluated carefully for signs of drip-
site-related infection.
Finally, efforts should be made to reduce the incidence of nosocomial 
infections as a whole, through increased emphasis on infection-control 
practices such as handwashing and aseptic technique. Although it is 
now more than 100 years since the pioneering work of Semmelweis, his 
lessons remain pertinent today.
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